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A B S T R A C T
Surgically treated patients with oral, head and neck cancer commonly develop mucositis during additional irradia-
tion therapy. Oral mucosa inflammation other than irradiation is mostly caused by Candida albicans, yeast of Candida
genus. This study evaluated possible connection between grades of oral mucositis and oral yeast profile in irradiated pa-
tients before, during and after irradiation. In 25 examined patients mucosits grades »0« to »2« before irradiation with
20% positive smears and only two different species of yeasts (C. krusei 4%, C. albicans 16%) during the irradiation
changed into »0« to »4« and 36% positive smears with five different species of oral yeasts (C. albicans 12%, C. glabrata
12%, C. parapsilosis 4%, C. guilliermondii 4% and Saccharomyces cerevisiae 4%). Three weeks after irradiation was fin-
ished mucositis decreased into »1« to »3« with 20% positive smears and again only two species of yeasts (C. albicans 16%,
C. guilliermondii 4%). Mucositis grades was increased significantly (p=0.0037) with changes in fungi profile.
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Introduction
Patients that suffer from malignant mouth, head and
neck diseases often develop mucositis as a result of addi-
tional radiotherapy that follows surgical removal of a
tumor1–8.
Mucositis is usually defined as an inflammation of the
oral (and gastrointestinal) mucosa1–3.
It is known that mucositis is a more complexed prob-
lem than inflammation of oral mucose alone. It results
from the destruction of rapidly dividing epithelial cells
and from vascular changes of lamina propria of the oral
mucose epithelium by activating NF-kB and secondary
release of inflammatory mediators such as TNF-alpha
and interleukin-1 causing a variety of changes of oral
mucosa, from mild atrophy to severe ulcerations9–14. Se-
verity of mucositis is influenced by patient related fac-
tors and treatment related factors. Treatment related
factors such as increased total dose of radiation, fraction
size and volume of normal tissue in the irradiated field
all increase the risk of mucositis15,16.
Patients related factors such as age, nutrition, smok-
ing, alcohol consumption, dental status, prostetic den-
tures, overall condition of the oral mucosa prior to ther-
apy, pre-existing oral diseases, pre-existing collagen and
vascular disorders, pre-existing xerostomia and cancer
status at the beginning of the therapy all influence the
development and severity of mucositis3–5,17,18. The World
Health Organization (WHO) defines mucositis as ana-
tomic, symptomatic and functional manifestationes which
are presented in five grades of severity: »0« with no man-
ifestation, »1« soreness and erythema, »2« eryhema, ul-
cers, but patient can swallow solid food, »3« ulcers with
extensive erythema ulcers, patient cannot swallow solid
food, and grade »4« mucositis to the extent that feeding
is not possible19.
In head and neck cancer therapy, all patients under-
going irradiation will develop grades »1« or »2« of muco-
sitis10,19. More severe mucositis (grade »3« or »4«) will be
developed in approximately 41% of patients receiving a
combination of radiation and chemotherapy and 21% pa-
tients receiving a chemotherapy alone8,10,18.
Clinical signs of mucosal damage and cell death usu-
ally appear during the second week of radiation thera-
py19. Irradiation therapy also affects salivary glands cau-
sing reduced salivary flow or xerostomia. Severity of
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xerostomia depends on dosage and duration of radiation
therapy20.
Mucosal damage and xerostomia allow a possibility of
microorganism superinfection21,22. Candida albicans is
an opportunistic microorganism of oral mucosa in adult
humans that causes no symptoms in healthy oral mu-
cosa. Enlarged number of C. albicans colonies or profile
changes may cause candidiasis – an illness with acute or
cronical symptoms and atrophic or hypertrophic oral mu-
cosa changes1–3. Oral mucosa changes caused by Candida
species may have clinical manifestations similar to the
mucositis caused by irradiation with mild atrophy to se-
vere ulcerations. Those changes may be clinically de-
scribed at the same way that WHO use to describe and
graduate mucositis with soreness, erosions and erythe-
ma. Irradiation therapy may induce genotype and pheno-
type changes of oral microorganisms. Many authors de-
scribe profile changes of candida species in oral mucosa
during irradiation therapy23–38.
During irradiation therapy the predominance of C.
albicans in oral mucosa in healthy circumstances is
changed to non-albicans species predominance. Candida
species found and described in oral mucosa during irradi-
ation therapy are C. pseudotrophicalis, C. guilliermon-
dii, C. krusei, C. glabrata, C. tropicalis, C. dubliniensis,
C. lusitoniae, C. kefyr and C. parapsilopsis23–38. The most
of changes in number of different Candida species were
found after second week of irradiation therapy which
correlated with more severe mucositis grades28–38.
The aim of this study was to establish whether can-
dida species profile changes influence and worsen the
mucositis during the irradiation therapy.
Materials and Methods
We tested 25 patients (22 males – 88% and 3 females –
12%) aged 47 to 84 (average age 63) with oral, head and
neck cancer. All of them were surgically treated and irra-
diated. The dose of irradiation was 6000 cGy in 30 sepa-
rated doses of 200 cGy each. All patients had oral mucosa
examined and controlled on several occasions with muco-
sitis grades established and oral swabs on fungi taken.
Oral mucositis was ranged from »0« to »4« according to
the WHO recommendation. Oral swabs were distributed
in agar Sabouraud dextrose/chlorophenicol and incuba-
ted at 37 degrees of Celsius for 18 hours. Emerging colo-
nies were identified biochemically and through the ger-
minative tube test.
Patients were examined prior the irradiation, during
the second week of irradiation and three weeks after the
irradiation had been finished and oral statuses (muco-
sitis and oral swabs findings) of the same patient were
compared.
Cochran’s Q and McNamara’s tests were used for
comparison of oral swabs findings and mucositis grades
before, during and after irradiation therapy. Correlation
between mucositis and oral swabs findings were tested
with ÷2-test and the statistical significance was set at
p<0.05. Data were analyzed by statistical software
MedCalc for Windows, version 11.5.1.0 (MedCalc Soft-
ware, Mariakerke, Belgium).
Results
Prior the irradiation all patients had their oral mu-
cosa examined and possible changes were verified accord-
ing to symptoms similar to those used by WHO in mu-
cositis grade ranging. A total of 32% (N=8) patients were
without any oral symptoms with preserved integrity of
normally colored and normally functional oral mucosa
and 68% patients (N=17) had some clinical symptoms
similar to mucositis like sorrenses, erythema, small ul-
cerations but with ability to eat solid food (Table 1).
In the second week of irradiation mucositis grades
were higher.
Only 8% (N=2) patients were without any symptoms,
60% (N=15) patients had grades from »1« to »2«, 24%
(N=6) had grade »3« with extensive erythema, deep ul-
cers and inability to eat solid food and 8% (N=2) had
grade »4« without posibility of eating anything (Table 1).
Three weeks after irradiation had been finished most
of the patients (88%, N=22) had mucositis grades from
»1« to »2« and 12% (N=3) had grade »3«. No patients
were without symptoms and no patients had grade »4« at
this stage of observation (Table 1).
According to a rank correlation test, mucositis during
the irradiation compared to the mucositis before irradia-
tion had started, were higher and remained higher for
three weeks after irradiation with statistical significance
of p=0.012.
Before irradiation 80% (N=20) of all patients had
negative swabs. Among 20% (N=5) positive oral swabs
two different species of yeast were found: C. albicans in
16% (N= 4) patients and C. krusei in 4% (N= 1) patients
(Table 2).
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TABLE 1
MUCOSITIS GRADES BEFORE, DURING AND AFTER IRRADIATION
Mucositis grade (according WHO) 0 1 2 3 4
Before irradiation 8* (32%) 9 (36%) 8 (32%)
Second week of irradiation 2 (8%) 5 (20%) 10 (40%) 6 (24%) 2 (8%)
Three weeks after irradiation finished 17 (68%) 5 (20%) 3 (12%)









In the second week of irradiation 64% (N=16) of all
patients had negative oral swabs. Among 36% (N=9) pos-
itive oral swabs there were five different species of yeast:
C. albicans, C. glabrata, C. parapsilosis, Saccharomyces
cerevisiae and C. guilliermondii. A percentage of all
found yeasts compared to C. albicans percentage were
two times higher (Table 2).
Three weeks after irradiation had been finished, 80%
(N=20) of oral swabs were found negative and among
20% (N=5) of positive swabs, two different species of
yeast were found, 16 % (N=4) of C. albicans and 4 %
(N=1) of C. krusei. The distribution of oral yeast species
was the same before and after the irradiation with preva-
lence of C. albicans (Table 2). Mucositis appearance was
more frequent during therapy and three weeks after
with statistical significance of p<0.001.
The highest mucositis grade found during the irradia-
tion was »4«, while prior the irradiation the highest
grades were »2« and »3«, the same as after irradiation
therapy. Oral mucositis grades had increased during irra-
diation period with statistical significance of p=0.012.
Mucositis and positive oral swabs before the irradia-
tion and three weeks after the irradiation were the same
(16%). We have not found statistically significant correla-
tion between the presence of Candida and mucositis be-
fore irradiation or three weeks after (p>0.05).
Oral mucositis increased simultaneously with increa-
sed number of oral yeast species in positive oral swabs
findings with statistical significance of p=0.0037 during
the irradiation therapy.
Discussion
In most studies patients surgically treated and irradi-
ated after suffering from malignant mouth, head and
neck diseases were examined during the therapy for vari-
ous factors such as clinical and microbiological changes
and for possibilities of oral functions.
Oral mucositis has been identified as the most debili-
tating side effect of cancer therapy by patients. Various
authors describe mucositis as oral mucosa disease caused
by destruction of rapidly dividing epithelial cells, exclu-
sively caused by irradiation without any bacterial infec-
tion1–3. Some other authors defined mucositis as oral and
gastrointestinal acute mucosa disease directly caused by
irradiation, chemotherapy, mechanical causes (solid food,
brushing), thermic exposure (hot food), tumor topic (di-
rect) influence, tumor indirect influence causing immu-
nity disorders, xerostomia, due to the poor oral hygiene
and current chronic diseases such as candidiasis6,10. The
terms stomatitis and mucositis have been used inter-
changeably when describing inflammatory oral condi-
tions. Assessment scales must precisely describe mucosal
damage, reproducibly measure severity and objectively
classify changes. The WHO is ranging mucositis by five
grades from »0« to »4« according to clinical changes and
functional possibilities.
Patients are usually examined for mucositis during ir-
radiation therapy, mostly after second week of irradia-
tion and three or four weeks after irradiation has been
finished39,40. In our study we also assessed mucositis be-
fore irradiation had even started, using the same criteria
as the WHO has recommended.
We found that 32% (N=8) of our patients had no
mucositis (grade »0«) and that 68% (N=17) had mild
mucositis before irradiation. None of our patients had se-
vere mucositis (grades »3« or »4«) prior to radiotherapy.
Other studies had not assessed oral mucositis prior
the irradiation therapy. The reason was that mucositis is
exclusively caused by irradiation without any bacterial
infection, so other autors found no reason to examine
mucosal inflammation. We found a number of positive
oral smears on yeast species among our patients prior a
therapy. We found that 80% (N=20) of our patients had
negative oral smears before irradiation had started and
20% (N=5) were positive on Candida species.
C. albicans was found in 16% (N=4) of patients and C.
krusei in 4% (N=1) of them. These results didn’t corre-
late with findings in other similar studies. Brasilians had
42.9% positive patients colonized exclusively with C.
albicans before irradiation started, Mexicans 43% and
Jordanian 72.6%24,28,30. Although those numbers were
not similar to our findings, the distribution of Candida
species was. In all studies C. albicans prevaleted. Beside
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TABLE 2
YEAST SMEARS BEFORE, DURING AND AFTER IRRADIATION
Yeast-like fungi species Negative smears Positive smears Isolates





























C. albicans we found C. krusei, Brazilians found C. dubli-
niensis and Jordanians found C. glabrata.
Mucositis and positive oral smears at the same time
had 16% (N=4) of our patients. We didn’t find statisti-
cally significant correlation between the presence of can-
dida in oral mucosa and mucositis before irradiation
(p>0.05). So, our conclusion was that mucositis in those
cases was caused by presence of bacteria of some kind or
due to mechanical or chemical factors.
During the second week of irradiation, mucositis per-
centage among our patients increased to 92% (N=23). A
total of 60% (N=16) had grades from »1« to »2«, 24%
(N=6) had grade »3« and 8% (N=2) had grade »4«. It is
known that mucositis grows with advanced radiotherapy
and in the second week of radiotherapy mucositis is sup-
posed to be the worst. The mean overall incidence of
mucositis was 80% among patients with conventional ir-
radiation therapy in 33 studies18. The frequency of muco-
sitis was the highest in patients treated with alterated
fractionation of radiotherapy affecting 100% patients
overall.
Grades »3« and »4« of mucositis in those studies expe-
rienced 34% of patients with conventional irradiation
treatment which correlates with our findings (32%)18.
Mucositis occured in the second week of irradiation among
our patients in 92% of cases which was significantly more
(p=0.012) then prior the therapy.
In the second week of irradiation 64% (N=16) of our
patients had negative oral swabs. Among 36% positive
oral swabs C. albicans was found in 12% (N=3) cases, C.
glabrata also in 12% (N=3), C. parapsilosis in 4% (N=1)
of cases, C. guilliermondii in 4% (N=1), and Saccharo-
myces cerevisiae, yeast of non-candida origine, in 4%
(N=1) of cases. Altough there were more positive oral
swabs in the second week of irradiation compared to the
findings before, there was no statistical significance (p>
0.05). Mucositis and positive oral swabs on yeast species
during irradiation therapy at the same time were found
in 40% (N=10) of our patients.
Oral mucositis increased to the grade »3« and »4« si-
multaneously with increased number of yeast species
found in oral mucosa with statistical significance (p=
0.0037).
Three weeks after irradiation therapy had been fin-
ished, mucositis rates were »1« and »2« in 88% (N=22)
and »3« in 12% (N=3) of patients. None of the patients
were without any symptoms. As irradiation therapy has
lasted for four to six weeks and its effects were cumula-
tive we expected to find such results. It is similar to the
literature reports and incidence of mucositis appearance
of 80–100%41,42.
Oral swabs findings 3 weeks after irradiation had
been finished were negative in 80% (N=20) of our pa-
tients and were positive in 20 (N=5). C. albicans was
found in 16% (N=4) and C. krusei in 4% (N=1) of pa-
tients. These findings didn’t correlate with the literature
findings where incidence of positive oral swabs was
70.1%37,38. Our findings regarding distribution of yeast
species at this point were the same as before irradiation
had started with prevalence of C. albicans over C. krusei.
The percentage of patients with positive oral swabs was
similar as in literature43. Number of patients that had
mucositis and positive oral swabs at the same time three
weeks after irradiation had been finished were 16%.
Mucositis appeared more frequent three weeks after ir-
radiation then before with statistical significance (p=
0.001) and more frequent after (100%) then during (92%)
the therapy but without statistical significance (p=0.07).
We didn’t find statistically significant difference among
distribution of candida before and after irradiation (p>
0.05) which was not in agreement with the current
literature30–38. During irradiation therapy we had more
positive oral swabs then before the therapy had started
and after the therapy had finished but without statistical
significance. Also, we didn’t find any statistically signifi-
cant correlation between distribution of yeast species
and a grade of mucositis (p>0.05) three weeks after the
irradiation therapy had been finished.
Conclusion
We found the same percentage of patients with posi-
tive oral swabs before and after the irradiation therapy
with the same distribution of fungi – two species of
Candida: C. albicans and C. krusei. We also found the in-
cidence of mucositis significantly higher during the tera-
py and three weeks after the therapy had been finished.
Findings of positive oral swabs during irradiation were
also higher then before and after irradiation therapy but
without statistical significance. Oral mucositis increased
(to »3« and »4«) simultaneosly with increased number of
oral yeast species in positive oral swabs findings. Muco-
sitis appeared more frequently during irradiation ther-
apy, with increased positive oral swabs findings.
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STUPANJ MUKOZITISA I VRSTE KVASNICA
S A @ E T A K
Bolesnici operirani od tumora usta, glave i vrata ~esto oboljevaju od mukozitisa za vrijeme dodatnog lije~enja zra~e-
njem. Upala sluznice usta osim radijacijom mo`e biti izazvana C. albicans, gljivicom koja kao i druge vrste kandida
spada u rod kvasnica. Cilj ovog rada bio je utvrditi mogu}u povezanost stupnja mukozitisa i prisustva vi{e vrsta kvas-
nica kod bolesnika prije, za vrijeme i nakon zra~enja. Od 25 ispitanika prije zra~enja njih 20% imalo je mukozitis stup-
nja 0–2 s pozitivnim brisom na kvasnice i samo dvije prona|ene vrste (C. albicans 16% i C. krusei 4%), {to se tijekom
zra~enja promijenilo u mukozitis stupnja 0–4 kod 36% bolesnica s pozitivnim brisom na kvasnice i 5 razli~itih vrsta (C.
albicans 12%, C. glabrata 12%, C. parapsilosis 4%, C. guilliermondii 4% i Saccharomyces cerevisiae 4%). Tri tjedna
nakon zavr{etka zra~enja mukozitis je ponovo bio inteziteta 1–3 sa 20% pozitivnih obrisaka na kvasnice i samo dvije
vrste (C. albicans 16% i C. krusei 4%). Mukozitis s pozitivnim obriskom istovremeno je imalo 16% bolesnika prije
zra~enja. Nije prona|ena statisti~ki zna~ajna povezanost pozitivnog nalaza kandide na oralnoj sluznici i mukozitisa
prije zra~enja (p>0,05). Stupanj mukozitisa pove}avao se statisti~ki zna~ajno (p=0,0037) s pove}anjem broja vrsta
kvasnica.
M. Ognjenovi} et al.: Mucositis and Yeast, Coll. Antropol. 37 (2013) 2: 443–447
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